[Skip to Navigation]
Evidence to Practice
January 2016

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol Levels: Effectiveness and Value

Author Affiliations
  • 1Division of General Internal Medicine, Department of Medicine, University of California, San Francisco
  • 2Division of Cardiology, Department of Medicine, University of California San Francisco
  • 3Department of Epidemiology and Biostatistics, University of California, San Francisco
  • 4Center for Healthcare Value, University of California, San Francisco
  • 5Institute for Clinical and Economic Review, Boston, Massachusetts
JAMA Intern Med. 2016;176(1):107-108. doi:10.1001/jamainternmed.2015.7248
Add or change institution
×